Sweden's pharmaceutical sales, at pharmacy purchasing prices, have expanded by 5% in the first quarter of 2008 compared with the like period of 2007, from 6.99 billion Swedish kronor ($1.17 billion) to 7.34 billion kronor, according to IMS Health. The figure includes both human and animal drugs, with the latter accounting for 1.5% of the total. Among the factors affecting the data were the authorization of nicotine replacement product sales outside pharmacies as well as the fact that the first quarter had an extra day in the current year, compared to 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze